Chardan Capital 重申对 Arrowhead Pharmaceuticals 的“买入”评级，目标价为 60 美元。 Arrowhead Pharmaceuticals receives reaffirmed "buy" rating at $60 target price from Chardan Capital.

Chardan Capital 重申 Arrowhead Pharmaceuticals (ARWR) 的“买入”评级，目标价为 60 美元，表明该股较前收盘价有 172.48% 的上涨潜力。 Arrowhead Pharmaceuticals' (ARWR) "buy" rating is reaffirmed at Chardan Capital with a $60 target price, indicating a potential upside of 172.48% from the stock's previous close. 其他分析师最近的报告包括加拿大皇家银行的“跑赢大盘”评级和 50 美元的目标价、HC Wainwright 的“买入”评级和 90 美元的目标价，以及花旗集团的“中性”评级和 34 美元的目标价。 Recent reports from other analysts include Royal Bank of Canada's "outperform" rating and $50 price objective, HC Wainwright's "buy" rating and $90 price objective, and Citigroup's "neutral" rating with a $34 price objective.